{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:07:55Z","timestamp":1750284475983,"version":"3.37.3"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["221S034"],"award-info":[{"award-number":["221S034"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.neulet.2024.137846","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T23:16:14Z","timestamp":1717024574000},"page":"137846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859"],"prefix":"10.1016","volume":"834","author":[{"given":"Dilek","family":"Kaya-Aky\u00fczl\u00fc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2262-5613","authenticated-orcid":false,"given":"Selin","family":"\u00d6zkan-Kotilo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Dan\u0131\u015fman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceylan","family":"Bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2024.137846_b0005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1176\/appi.ajp.2018.18030352","article-title":"Molecular Genetics and New Medication Strategies for Opioid Addiction","volume":"175","author":"Hurd","year":"2018","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.neulet.2024.137846_b0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13722-022-00326-1","article-title":"Buprenorphine\/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial","volume":"17","author":"Ellerbroek","year":"2022","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.neulet.2024.137846_b0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40263-018-0513-9","article-title":"Pharmacogenetics of Opioid Use Disorder Treatment","volume":"32","author":"Crist","year":"2018","journal-title":"CNS Drugs."},{"key":"10.1016\/j.neulet.2024.137846_b0020","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41397-018-0065-x","article-title":"Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder","volume":"19","author":"Crist","year":"2019","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.neulet.2024.137846_b0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction","volume":"32","author":"Neumann","year":"2013","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neulet.2024.137846_b0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10550887.2019.1690929","article-title":"Randomized clinical trial comparing buprenorphine\/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction","volume":"38","author":"Neumann","year":"2020","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neulet.2024.137846_b0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1151\/spp04224","article-title":"Practical considerations for the clinical use of buprenorphine","volume":"2","author":"Jones","year":"2004","journal-title":"Sci. Pract. Perspect."},{"key":"10.1016\/j.neulet.2024.137846_b0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/15622975.2021.2012397","article-title":"A potential paradigm shift in opioid crisis management: The role of pharmacogenomics, World","volume":"23","author":"Eapen-John","year":"2022","journal-title":"J Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2024.137846_b0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41397-020-00198-1","article-title":"A review of the existing literature on buprenorphine pharmacogenomics","volume":"21","author":"Meaden","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.neulet.2024.137846_b0050","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1208\/aapsj080121","article-title":"Symbiotic relationship of pharmacogenetics and drugs of abuse","volume":"8","author":"Rutter","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.neulet.2024.137846_b0055","unstructured":"L. Dean, Thioridazine Therapy and CYP2D6 Genotypes. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012, 2017."},{"key":"10.1016\/j.neulet.2024.137846_b0060","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1177\/10600280211003875","article-title":"Pharmacogenomics in Pain Management: A Review of Relevant Gene-Drug Associations and Clinical Considerations","volume":"55","author":"Brandl","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neulet.2024.137846_b0065","unstructured":"U.S. Food and Drug Administration [Internet]. 2020. Center for Drug Evaluation and Research. [cited 2021 Dec 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020733s007s008lbl.pdf."},{"key":"10.1016\/j.neulet.2024.137846_b0070","article-title":"The Opioid Crisis: A Review of Genetic Predispositions, Current Policy and Future Directions","volume":"18","author":"Wiseman","year":"2021","journal-title":"Impulse"},{"key":"10.1016\/j.neulet.2024.137846_b0075","first-page":"688","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2024.137846_b0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000097349","article-title":"Molecular biology of opioid receptors","volume":"4","author":"Singh","year":"1997","journal-title":"Neuroimmunomodulation."},{"key":"10.1016\/j.neulet.2024.137846_b0085","doi-asserted-by":"crossref","first-page":"32618","DOI":"10.1074\/jbc.M504942200","article-title":"Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G","volume":"280","author":"Zhang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2024.137846_b0090","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1213\/01.ane.0000231634.20341.88","article-title":"A Genetic Association Study of the Functional A118G Polymorphism of the Human Mu-Opioid Receptor Gene in Patients with Acute and Chronic Pain","volume":"103","author":"Janicki","year":"2006","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neulet.2024.137846_b0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1471-4159.2007.04738.x","article-title":"The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor","volume":"103","author":"Kroslak","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2024.137846_b0100","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1073\/pnas.1018699108","article-title":"Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers","volume":"108","author":"Ray","year":"2011","journal-title":"Proc. Natl. Acad. Sci. u.s.a."},{"key":"10.1016\/j.neulet.2024.137846_b0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/oby.2008.504","article-title":"OPRM1 gene is associated with BMI in Uyghur population","volume":"17","author":"Xu","year":"2009","journal-title":"Obesity (silver Spring)."},{"key":"10.1016\/j.neulet.2024.137846_b0110","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0006-291X(03)00089-5","article-title":"Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X","volume":"301","author":"Pan","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neulet.2024.137846_b0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuroscience.2004.12.033","article-title":"Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm","volume":"133","author":"Pan","year":"2005","journal-title":"Neuroscience."},{"key":"10.1016\/j.neulet.2024.137846_b0120","doi-asserted-by":"crossref","unstructured":"Y.X. Pan, J. Xu, E. Bolan, A. Chang, L. Mahurter, G. Rossi, G.W. Pasternak, Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F.FEBS Lett. 466 (2000) 337\u2013340. Doi: 10.1016\/s0014-5793(00)01095-4.","DOI":"10.1016\/S0014-5793(00)01095-4"},{"key":"10.1016\/j.neulet.2024.137846_b0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0014-5793(95)00028-8","article-title":"Cloning and expression of an isoform of the rat mu opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1","volume":"359","author":"Zimprich","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neulet.2024.137846_b0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0014-5793(94)01129-X","article-title":"Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain","volume":"354","author":"Bare","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neulet.2024.137846_b0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40122-015-0041-y","article-title":"The Opposing Roles of IVS2+691 CC Genotype and AC\/AG Diplotype of 118A>G and IVS2+691G>C of OPRM1 Polymorphisms in Cold Pain Tolerance Among Opioid-Dependent Malay Males on Methadone Therapy","volume":"4","author":"Zahari","year":"2015","journal-title":"Pain Ther."},{"key":"10.1016\/j.neulet.2024.137846_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2022.103902","article-title":"Effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on sublingual buprenorphine metabolism in heroin addicts: An improved PCR-RFLP assay for the detection of rs7662029 polymorphism","volume":"94","author":"Kaya-Aky\u00fczl\u00fc","year":"2022","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.neulet.2024.137846_b0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-244X-13-107","article-title":"Association study of OPRM1 polymorphisms with Schizophrenia in Han Chinese population","volume":"13","author":"Ding","year":"2013","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.neulet.2024.137846_b0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajmg.b.30105","article-title":"Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence","volume":"133B","author":"Smith","year":"2005","journal-title":"Am. J. Med. Genet. b. Neuropsychiatr. Genet."},{"key":"10.1016\/j.neulet.2024.137846_b0155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s001090050246","article-title":"The human mu opioid receptor gene: 5' regulatory and intronic sequences","volume":"76","author":"Wendel","year":"1998","journal-title":"J. Mol. Med. (berl)"},{"key":"10.1016\/j.neulet.2024.137846_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136364","article-title":"Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population","volume":"768","author":"Yuferov","year":"2022","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2024.137846_b0165","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/syn.21727","article-title":"Isolating and characterizing three alternatively spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and mMOR-1P","volume":"68","author":"Xu","year":"2014","journal-title":"Synapse"},{"key":"10.1016\/j.neulet.2024.137846_b0170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/humu.9026","article-title":"Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin","volume":"19","author":"Shi","year":"2002","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.neulet.2024.137846_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/1744-9081-2-28","article-title":"The mu-opioid receptor gene and smoking initiation and nicotine dependence","volume":"2","author":"Zhang","year":"2006","journal-title":"Behav. Brain. Funct."},{"key":"10.1016\/j.neulet.2024.137846_b0180","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1365-2044.2008.05760.x","article-title":"Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females","volume":"63","author":"Huang","year":"2008","journal-title":"Anaesthesia"},{"key":"10.1016\/j.neulet.2024.137846_b0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40122-016-0044-3","article-title":"The AC\/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among Opioid-Dependent Patients on Methadone Maintenance Therapy","volume":"5","author":"Zahari","year":"2016","journal-title":"Pain Ther."},{"key":"10.1016\/j.neulet.2024.137846_b0190","first-page":"e17217","article-title":"Sleep quality and OPRM1 polymorphisms: a cross-sectional study among opioid-naive individuals Braz","volume":"54","author":"Zahari","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.neulet.2024.137846_b0195","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1093\/hmg\/9.19.2895","article-title":"Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence","volume":"9","author":"Hoehe","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neulet.2024.137846_b0200","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40262-014-0155-0","article-title":"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence","volume":"53","author":"Nasser","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neulet.2024.137846_b0205","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euroneuro.2012.02.002","article-title":"Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients","volume":"22","author":"Wang","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2024.137846_b0210","doi-asserted-by":"crossref","unstructured":"C.M. Laffont, E. Ngaimisi, M. Gopalakrishnan, V. Ivaturi, M. Young, M.K. Greenwald, C. Heidbreder, Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. Front Pharmacol. 13 (2022) 1052113. Doi: 10.3389\/fphar.2022.1052113.","DOI":"10.3389\/fphar.2022.1052113"},{"key":"10.1016\/j.neulet.2024.137846_b0215","first-page":"E695","article-title":"Resistin Gene Polymorphism Is an Influencing Factor of Postoperative Pain for Chinese Patients","volume":"23","author":"Xie","year":"2020","journal-title":"Pain Physician."},{"key":"10.1016\/j.neulet.2024.137846_b0220","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s13181-012-0286-3","article-title":"Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population","volume":"9","author":"Manini","year":"2013","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.neulet.2024.137846_b0225","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1399-6576.2004.00517.x","article-title":"The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease","volume":"48","author":"Klepstad","year":"2004","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.neulet.2024.137846_b0230","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2217\/14622416.9.11.1605","article-title":"Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype","volume":"9","author":"Hayashida","year":"2008","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.neulet.2024.137846_b0235","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-5793(94)80368-4","article-title":"Human \u00b5 opiate receptor","volume":"338","author":"Wang","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neulet.2024.137846_b0240","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3390\/biom11101525","article-title":"Alternative Pre-mRNA Splicing of the Mu Opioid Receptor Gene, OPRM1: Insight into Complex Mu Opioid Actions","volume":"11","author":"Liu","year":"2021","journal-title":"Biomolecules."},{"key":"10.1016\/j.neulet.2024.137846_b0245","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/pr.112.007138","article-title":"Mu opioids and their receptors: evolution of a concept","volume":"65","author":"Pasternak","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neulet.2024.137846_b0250","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1097\/00001756-200110080-00017","article-title":"Differential in vivo internalization of MOR-1 and MOR-1C by morphine","volume":"12","author":"Abbadie","year":"2021","journal-title":"Neuroreport."},{"key":"10.1016\/j.neulet.2024.137846_b0255","doi-asserted-by":"crossref","first-page":"13652","DOI":"10.1074\/jbc.273.22.13652","article-title":"Carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist-mediated internalization and receptor resensitization","volume":"273","author":"Koch","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2024.137846_b0260","doi-asserted-by":"crossref","first-page":"31408","DOI":"10.1074\/jbc.M100305200","article-title":"C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization","volume":"276","author":"Koch","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2024.137846_b0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/syn.10277","article-title":"Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm","volume":"51","author":"Bolan","year":"2004","journal-title":"Synapse."},{"key":"10.1016\/j.neulet.2024.137846_b0270","doi-asserted-by":"crossref","first-page":"35614","DOI":"10.1074\/jbc.M806588200","article-title":"Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors","volume":"283","author":"Tanowitz","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2024.137846_b0275","first-page":"99","article-title":"Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent","volume":"5","author":"Al-Eitan","year":"2012","journal-title":"Pharmgenomics. Pers. Med."},{"key":"10.1016\/j.neulet.2024.137846_b0280","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biopsych.2015.01.003","article-title":"Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1","volume":"78","author":"Hancock","year":"2015","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2024.137846_b0285","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fgene.2018.00450","article-title":"Methadone Dosage and Plasma Levels, SNPs of OPRM1 Gene and Age of First Drug Use Were Associated With Outcomes of Methadone Maintenance Treatment","volume":"9","author":"Peng","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.neulet.2024.137846_b0290","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ajp.2009.08081167","article-title":"Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder","volume":"167","author":"Garriock","year":"2010","journal-title":"Am. J. Psychiatry."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394024002246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394024002246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T23:45:17Z","timestamp":1717803917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394024002246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":58,"alternative-id":["S0304394024002246"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2024.137846","relation":{},"ISSN":["0304-3940"],"issn-type":[{"type":"print","value":"0304-3940"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2024.137846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"137846"}}